Elevance Health, Inc. $ELV Shares Sold by Fjarde AP Fonden Fourth Swedish National Pension Fund

Fjarde AP Fonden Fourth Swedish National Pension Fund reduced its position in shares of Elevance Health, Inc. (NYSE:ELV) by 11.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 68,952 shares of the company’s stock after selling 9,260 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Elevance Health were worth $24,171,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the company. Norges Bank bought a new position in Elevance Health during the 4th quarter worth $1,058,165,000. Bank of New York Mellon Corp grew its stake in Elevance Health by 79.3% during the 4th quarter. Bank of New York Mellon Corp now owns 2,408,704 shares of the company’s stock worth $844,371,000 after buying an additional 1,065,065 shares during the last quarter. Artisan Partners Limited Partnership grew its stake in Elevance Health by 24.5% during the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after buying an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC grew its stake in Elevance Health by 25.0% during the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after buying an additional 798,457 shares during the last quarter. Finally, Brave Warrior Advisors LLC grew its stake in Elevance Health by 65.3% during the 3rd quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after buying an additional 724,349 shares during the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ELV has been the subject of a number of recent research reports. Morgan Stanley upped their price objective on Elevance Health from $352.00 to $404.00 and gave the stock an “equal weight” rating in a research note on Thursday. UBS Group upped their price objective on Elevance Health from $400.00 to $460.00 and gave the stock a “buy” rating in a research note on Friday, May 22nd. JPMorgan Chase & Co. upped their price objective on Elevance Health from $397.00 to $411.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Mizuho upped their price objective on Elevance Health from $385.00 to $435.00 and gave the stock an “outperform” rating in a research note on Wednesday, May 20th. Finally, Truist Financial upped their price objective on Elevance Health from $375.00 to $450.00 and gave the stock a “buy” rating in a research note on Monday. Fourteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and a consensus target price of $411.11.

Elevance Health Price Performance

Shares of ELV opened at $415.88 on Friday. The firm has a market capitalization of $90.31 billion, a price-to-earnings ratio of 17.69, a price-to-earnings-growth ratio of 2.32 and a beta of 0.67. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $416.56. The stock’s fifty day moving average is $354.74 and its 200-day moving average is $341.76.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating analysts’ consensus estimates of $10.74 by $1.84. The company had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The company’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period last year, the company earned $11.97 earnings per share. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Equities analysts anticipate that Elevance Health, Inc. will post 26.94 EPS for the current year.

Elevance Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s dividend payout ratio (DPR) is 29.26%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.